KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exact Sciences (EXAS) Equity Average (2016 - 2025)

Exact Sciences (EXAS) has disclosed Equity Average for 15 consecutive years, with $2.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 12.65% to $2.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 billion, a 12.65% decrease, with the full-year FY2025 number at $2.4 billion, down 13.42% from a year prior.
  • Equity Average was $2.5 billion for Q4 2025 at Exact Sciences, down from $2.5 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $3.6 billion in Q2 2021 to a low of $2.4 billion in Q1 2025.
  • A 5-year average of $3.0 billion and a median of $3.1 billion in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 93.93% in 2021, then decreased 23.56% in 2025.
  • Exact Sciences' Equity Average stood at $3.4 billion in 2021, then decreased by 10.13% to $3.1 billion in 2022, then increased by 1.87% to $3.1 billion in 2023, then decreased by 10.43% to $2.8 billion in 2024, then decreased by 12.65% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Equity Average are $2.5 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.4 billion (Q2 2025).